Danaher Corporation (DHR)vsGuardant Health Inc (GH)
DHR
Danaher Corporation
$184.30
+0.57%
HEALTHCARE · Cap: $117.48B
GH
Guardant Health Inc
$125.61
-5.60%
HEALTHCARE · Cap: $17.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 2194% more annual revenue ($24.78B vs $1.08B). DHR leads profitability with a 14.9% profit margin vs -40.1%. DHR earns a higher WallStSmart Score of 58/100 (C).
DHR
Buy58
out of 100
Grade: C
GH
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-60.8%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Intrinsic value data unavailable for GH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Revenue surging 48.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
0.0% earnings growth
ROE of -4584.0% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : GH
The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 48.3% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : GH
The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
DHR profiles as a value stock while GH is a hypergrowth play — different risk/reward profiles.
GH carries more volatility with a beta of 1.62 — expect wider price swings.
GH is growing revenue faster at 48.3% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Guardant Health Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?